Viridian Therapeutics, Inc. ( (VRDN) ) has released its Q4 earnings. Here is a breakdown of the information Viridian Therapeutics, Inc. presented to its investors.
Viridian Therapeutics, Inc. is a biotechnology company dedicated to developing and commercializing innovative treatments for serious and rare diseases, with a focus on thyroid eye disease (TED) and autoimmune disorders.
In its latest earnings report, Viridian Therapeutics announced significant progress in its clinical trials and a strong financial position. The company reported positive phase 3 data for its lead TED program, veligrotug, and is on track for a Biologics License Application submission in the second half of 2025. Additionally, Viridian has a robust cash position of $717.6 million, providing a financial runway into the second half of 2027.
Key highlights from the report include the successful achievement of all primary and secondary endpoints in the THRIVE and THRIVE-2 trials for veligrotug, indicating a differentiated clinical profile with fewer infusions and a rapid onset of treatment effect. The company is also advancing its subcutaneous VRDN-003, with topline data expected in the first half of 2026. Furthermore, Viridian is progressing with its FcRn inhibitor portfolio, anticipating proof-of-concept data for VRDN-006 in the third quarter of 2025.
Financially, Viridian’s research and development expenses increased to $238.3 million in 2024, reflecting the ongoing clinical trials and expansion of its FcRn inhibitor portfolio. Despite a net loss of $269.9 million for the year, the company’s cash reserves have grown significantly, supporting its strategic initiatives.
Looking ahead, Viridian Therapeutics remains focused on advancing its clinical programs and preparing for potential market entries. The management is optimistic about the transformative potential of its treatments and continues to execute its strategic plans to deliver innovative solutions for patients with rare diseases.